雅培Abbott Laboratories （ABT）2025年第三季度业绩报告（英文版）（16页）.pdf

1、Abbott Reports Third-Quarter 2025 Results And Reaffirms Full-Year GuidanceThird-quarter reported sales growth of 6.9 percent;organic sales growth of 5.5 percent or 7.5 percentexcluding COVID-19 testing-related sales1Third-quarter GAAP diluted EPS of$0.94;adjusted diluted EPS of$1.30Reported operatin

2、g margin of 18.1 percent of sales;adjusted operating margin of 23.0 percent,which reflectsa 40 basis point increaseABBOTT PARK,Ill.,Oct.15,2025 /PRNewswire/-Abbott(NYSE:ABT)today announced financial results for the third quarterended Sept.30,2025.Third-quarter sales increased 6.9 percent on a report

3、ed basis,5.5 percent on an organic basis,or 7.5 percent whenexcluding COVID-19 testing-related sales1.Third-quarter GAAP diluted EPS of$0.94 and adjusted diluted EPS of$1.30,which excludes specified items.Year-to-date sales increased 6.1 percent on a reported basis,6.4 percent on an organic basis,or

4、 7.7 percent whenexcluding COVID-19 testing-related sales2.Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrowsthe range to$5.12 to$5.18,reflecting double-

5、digit growth at the midpoint.In July,Abbott announced it received regulatory approval in Japan for TriClip,a first of-its-kind,minimally invasivetreatment option for patients with tricuspid regurgitation,or a leaky tricuspid heart valve.In August,Abbott announced it received CE Mark for an expanded

6、indication for the companys Navitor transcatheteraortic valve implantation(TAVI)system to treat people with symptomatic,severe aortic stenosis who are at low orintermediate risk for open-heart surgery.In August,at the European Society of Cardiology(ESC)Congress,new treatment guidelines were issued t